{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:00:50Z","timestamp":1792670450015,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41401-021-00761-x","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T10:03:12Z","timestamp":1631008992000},"page":"1372-1382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Novel selective \u03ba agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion"],"prefix":"10.1038","volume":"43","author":[{"given":"Yuan-yuan","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-yu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-hui","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-rui","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-gen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"761_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neulet.2007.04.014","volume":"419","author":"CW Stevens","year":"2007","unstructured":"Stevens CW, Brasel CM, Mohan S. Cloning and bioinformatics of amphibian mu, delta, kappa, and nociceptin opioid receptors expressed in brain tissue: evidence for opioid receptor divergence in mammals. Neurosci Lett. 2007;419:189\u201394.","journal-title":"Neurosci Lett."},{"key":"761_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fgene.2012.00223","volume":"3","author":"RE Rodriguez","year":"2012","unstructured":"Rodriguez RE. Morphine and microRNA activity: is there a relation with addiction? Front Genet. 2012;3:223.","journal-title":"Front Genet."},{"key":"761_CR3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.clinthera.2019.02.009","volume":"41","author":"D Abushanab","year":"2019","unstructured":"Abushanab D, Alsoukhni O, AbouNahia F, Al-Badriyeh D. Clinical and economic analysis of morphine versus fentanyl in managing ventilated neonates with respiratory distress syndrome in the intensive care setting. Clin Ther. 2019;41:714\u201327 e8.","journal-title":"Clin Ther."},{"key":"761_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.neuropharm.2019.02.008","volume":"151","author":"EA Kiyatkin","year":"2019","unstructured":"Kiyatkin EA. Respiratory depression and brain hypoxia induced by opioid drugs: Morphine, oxycodone, heroin, and fentanyl. Neuropharmacology. 2019;151:219\u201326.","journal-title":"Neuropharmacology."},{"key":"761_CR5","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","volume":"370","author":"WD Chey","year":"2014","unstructured":"Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387\u201396.","journal-title":"N Engl J Med."},{"key":"761_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ejphar.2008.02.028","volume":"584","author":"YM Tao","year":"2008","unstructured":"Tao YM, Li QL, Zhang CF, Xu XJ, Chen J, Ju YW, et al. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential. Eur J Pharmacol. 2008;584:306\u201311.","journal-title":"Eur J Pharmacol."},{"key":"761_CR7","doi-asserted-by":"crossref","unstructured":"Wang YJ, Tao YM, Li FY, Wang YH, Xu XJ, Chen J, et al. Pharmacological characterization of ATPM [(-)\u22123-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist\/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior. J Pharmacol Exp Ther. 2009;329:306\u201313.","DOI":"10.1124\/jpet.108.142802"},{"key":"761_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ejphar.2014.06.045","volume":"740","author":"JF Sun","year":"2014","unstructured":"Sun JF, Wang YH, Chai JR, Li FY, Hang A, Lu G, et al. Pharmacological characterization and therapeutic potential for the treatment of opioid abuse with ATPM-ET, an N-ethyl substituted aminothiazolomorphinan with kappa agonist and mu agonist\/antagonist activity. Eur J Pharmacol. 2014;740:455\u201363.","journal-title":"Eur J Pharmacol."},{"key":"761_CR9","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s00213-014-3436-2","volume":"231","author":"KB Freeman","year":"2014","unstructured":"Freeman KB, Naylor JE, Prisinzano TE, Woolverton WL. Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology. 2014;231:2751\u20138.","journal-title":"Psychopharmacology."},{"key":"761_CR10","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-017-0006-4","volume":"43","author":"JA Heinsbroek","year":"2018","unstructured":"Heinsbroek JA, Furbish AB, Peters J. A single, extinction-based treatment with a kappa opioid receptor agonist elicits a long-term reduction in cocaine relapse. Neuropsychopharmacology. 2018;43:1492\u20137.","journal-title":"Neuropsychopharmacology."},{"key":"761_CR11","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/0024-3205(82)90132-1","volume":"31","author":"RA Lahti","year":"1982","unstructured":"Lahti RA, VonVoigtlander PF, Barsuhn C. Properties of a selective kappa agonist. U-50,488H Life Sci. 1982;31:2257\u201360.","journal-title":"U-50,488H Life Sci."},{"key":"761_CR12","unstructured":"Vonvoigtlander PF, Lahti RA, Ludens JH. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther. 1983;224:7\u201312."},{"key":"761_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00002826-199619050-00009","volume":"19","author":"AC Pande","year":"1996","unstructured":"Pande AC, Pyke RE, Greiner M, Wideman GL, Benjamin R, Pierce MW. Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Clin Neuropharmacol. 1996;19:451\u20136.","journal-title":"Clin Neuropharmacol."},{"key":"761_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s002130100788","volume":"157","author":"SL Walsh","year":"2001","unstructured":"Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology. 2001;157:151\u201362.","journal-title":"Psychopharmacology."},{"key":"761_CR15","unstructured":"Vonvoigtlander PF, Lewis RA. Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid. J Pharmacol Exp Ther. 1988;246:259\u201362."},{"key":"761_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/BF00192549","volume":"46","author":"GH Rimoy","year":"1994","unstructured":"Rimoy GH, Wright DM, Bhaskar NK, Rubin PC. The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist. Eur J Clin Pharmacol. 1994;46:203\u20137.","journal-title":"Eur J Clin Pharmacol."},{"key":"761_CR17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3389\/fnins.2020.00765","volume":"14","author":"KF Paton","year":"2020","unstructured":"Paton KF, Biggerstaff A, Kaska S, Crowley RS, La Flamme AC, Prisinzano TE, et al. Evaluation of biased and balanced salvinorin A analogs in preclinical models of pain. Front Neurosci. 2020;14:765.","journal-title":"Front Neurosci."},{"key":"761_CR18","doi-asserted-by":"crossref","unstructured":"Morani AS, Kivell B, Prisinzano TE, Schenk S. Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav. 2009;94:244\u20139.","DOI":"10.1016\/j.pbb.2009.09.002"},{"key":"761_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/FBP.0b013e3283512c1e","volume":"23","author":"AS Morani","year":"2012","unstructured":"Morani AS, Schenk S, Prisinzano TE, Kivell BM. A single injection of a novel \u03ba opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats. Behav Pharmacol. 2012;23:162\u201370.","journal-title":"Behav Pharmacol."},{"key":"761_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1570159X13666150727220944","volume":"14","author":"GT Taylor","year":"2016","unstructured":"Taylor GT, Manzella F. Kappa opioids, salvinorin A and major depressive disorder. Curr Neuropharmacol. 2016;14:165\u201376.","journal-title":"Curr Neuropharmacol."},{"key":"761_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1254\/jjp.85.282","volume":"85","author":"T Endoh","year":"2001","unstructured":"Endoh T, Tajima A, Izumimoto N, Suzuki T, Saitoh A, Suzuki T, et al. TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys. Jpn J Pharmacol. 2001;85:282\u201390.","journal-title":"Jpn J Pharmacol."},{"key":"761_CR22","unstructured":"Nakao K, Hasebe K, Yoshikawa S, Ikeda K, Hirakata M, Miyamoto Y, et al. Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist. Nihon Shinkei Seishin Yakurigaku Zasshi. 2010;30(5-6):185-91."},{"key":"761_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.brainres.2003.09.057","volume":"995","author":"T Suzuki","year":"2004","unstructured":"Suzuki T, Izumimoto N, Takezawa Y, Fujimura M, Togashi Y, Nagase H, et al. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions. Brain Res. 2004;995:167\u201375.","journal-title":"Brain Res."},{"key":"761_CR24","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0024-3205(99)00417-8","volume":"65","author":"T Endoh","year":"1999","unstructured":"Endoh T, Matsuura H, Tajima A, Izumimoto N, Tajima C, Suzuki T, et al. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist. Life Sci. 1999;65:1685\u201394.","journal-title":"Life Sci."},{"key":"761_CR25","doi-asserted-by":"crossref","unstructured":"Cao D, Huang P, Chiu YT, Chen C, Wang H, Li M, et al. Comparison of pharmacological properties between the kappa opioid receptor agonist nalfurafine and 42B, its 3-dehydroxy analogue: disconnect between in vitro agonist bias and in vivo pharmacological effects. ACS Chem Neurosci. 2020;11:3036\u201350.","DOI":"10.1021\/acschemneuro.0c00407"},{"key":"761_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/IJNRD.S145720","volume":"11","author":"H Kozono","year":"2018","unstructured":"Kozono H, Yoshitani H, Nakano R. Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch(\u00ae) capsules 2.5 \u03bcg) in 3,762 hemodialysis patients with intractable pruritus. Int J Nephrol Renovasc Dis. 2018;11:9\u201324.","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"761_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000341268","volume":"36","author":"H Kumagai","year":"2012","unstructured":"Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, et al. Efficacy and safety of a novel \u0138-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol. 2012;36:175\u201383.","journal-title":"Am J Nephrol."},{"key":"761_CR28","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","volume":"25","author":"H Kumagai","year":"2010","unstructured":"Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25:1251\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"761_CR29","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1681\/ASN.2005020152","volume":"16","author":"B Wikstr\u00f6m","year":"2005","unstructured":"Wikstr\u00f6m B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol. 2005;16:3742\u20137.","journal-title":"J Am Soc Nephrol."},{"key":"761_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","volume":"44","author":"JJ Liu","year":"2019","unstructured":"Liu JJ, Chiu YT, DiMattio KM, Chen C, Huang P, Gentile TA, et al. Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in \u03ba opioid aversion. Neuropsychopharmacology. 2019;44:939\u201349.","journal-title":"Neuropsychopharmacology."},{"key":"761_CR31","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1021\/acschemneuro.6b00321","volume":"8","author":"W Li","year":"2017","unstructured":"Li W, Long JD, Qian YY, Long Y, Xu XJ, Wang YJ, et al. The Pharmacological heterogeneity of nepenthone analogs in conferring highly selective and potent \u03ba-opioid agonistic activities. ACS Chem Neurosci. 2017;8:766\u201376.","journal-title":"ACS Chem Neurosci."},{"key":"761_CR32","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1021\/acschemneuro.1c00034","volume":"12","author":"X Liu","year":"2021","unstructured":"Liu X, Jiang S, Kong L, Ye R, Xiao L, Xu X, et al. Exploration of the SAR connection between morphinan- and arylacetamide-based \u03ba opioid receptor (\u03baOR) agonists using the strategy of bridging. ACS Chem Neurosci. 2021;12:1018\u201330.","journal-title":"ACS Chem Neurosci."},{"key":"761_CR33","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1016\/j.bmc.2018.07.020","volume":"26","author":"HJ Sun","year":"2018","unstructured":"Sun HJ, Wang YH, Yuan CM, Kong LH, Xu XJ, Wang YJ, et al. 7\u03b2-Methyl substituent is a structural locus associated with activity cliff for nepenthone analogues. Bioorg Med Chem. 2018;26:4254\u201363.","journal-title":"Bioorg Med Chem."},{"key":"761_CR34","doi-asserted-by":"publisher","first-page":"11054","DOI":"10.1021\/acs.jmedchem.9b00857","volume":"62","author":"L Xiao","year":"2019","unstructured":"Xiao L, Wang Y, Zhang M, Wu W, Kong L, Ma Y, et al. Discovery of a highly selective and potent \u03ba opioid receptor agonist from N-cyclopropylmethyl-7\u03b1-phenyl-6,14-endoethanotetrahydronorthebaines with reduced central nervous system (CNS) side effects navigated by the message-address concept. J Med Chem. 2019;62:11054\u201370.","journal-title":"J Med Chem"},{"key":"761_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.bmc.2005.08.052","volume":"14","author":"W Li","year":"2006","unstructured":"Li W, Tang Y, Zheng YL, Qiu ZB. Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists. Bioorg Med Chem. 2006;14:601\u201310.","journal-title":"Bioorg Med Chem."},{"key":"761_CR36","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s00044-010-9471-6","volume":"20","author":"H Qi","year":"2011","unstructured":"Qi H, Wei LI, Qiu Y, Cui YY, Ma J, Gao XL, et al. Synthesis and evaluation of \u03ba-opioid receptor agonistic activity and antinociceptive effect of novel morphine analogues, 7\u03b1-phenyl-6\u03b1,14\u03b1-endo-etheno-tetrahydrothebaine with substituted o-, m- and p-amino group. Med Chem Res. 2011;20:1364\u201370.","journal-title":"Med Chem Res."},{"key":"761_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/aps.2014.145","volume":"36","author":"LS Zhang","year":"2015","unstructured":"Zhang LS, Wang J, Chen JC, Tao YM, Wang YH, Xu XJ, et al. Novel kappa-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation. Acta Pharmacol Sin. 2015;36:565\u201371.","journal-title":"Acta Pharmacol Sin."},{"key":"761_CR38","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1523\/JNEUROSCI.3466-17.2018","volume":"38","author":"YC Lu","year":"2018","unstructured":"Lu YC, Wang YJ, Lu B, Chen M, Zheng P, Liu JG. ACC to dorsal medial striatum inputs modulate histaminergic itch sensation. J Neurosci. 2018;38:3823\u201339.","journal-title":"J Neurosci."},{"key":"761_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32568-y","volume":"8","author":"YH Wang","year":"2018","unstructured":"Wang YH, Chai JR, Xu XJ, Ye RF, Zan GY, Liu GYK, et al. Pharmacological characterization of dezocine, a potent analgesic acting as a kappa partial agonist and mu partial agonist. Sci Rep. 2018;8:14087.","journal-title":"Sci Rep."},{"key":"761_CR40","doi-asserted-by":"publisher","first-page":"eaao4927","DOI":"10.1126\/science.aao4927","volume":"360","author":"JJ Liu","year":"2018","unstructured":"Liu JJ, Sharma K, Zangrandi L, Chen C, Humphrey SJ, Chiu YT, et al. In vivo brain GPCR signaling elucidated by phosphoproteomics. Science. 2018;360:eaao4927.","journal-title":"Science."},{"key":"761_CR41","doi-asserted-by":"publisher","unstructured":"Inan S, Cowan A. Antipruritic effects of kappa opioid receptor agonists: evidence from rodents to humans. Handb Exp Pharmacol. 2020. https:\/\/doi.org\/10.1007\/164_2020_420.","DOI":"10.1007\/164_2020_420"},{"key":"761_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0014-2999(01)01588-6","volume":"435","author":"Y Togashi","year":"2002","unstructured":"Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol. 2002;435:259\u201364.","journal-title":"Eur J Pharmacol."},{"key":"761_CR43","doi-asserted-by":"publisher","first-page":"12917","DOI":"10.1523\/JNEUROSCI.2444-15.2015","volume":"35","author":"JM Ehrich","year":"2015","unstructured":"Ehrich JM, Messinger DI, Knakal CR, Kuhar JR, Schattauer SS, Bruchas MR, et al. Kappa opioid receptor-induced aversion requires p38 MAPK activation in VTA dopamine neurons. J Neurosci. 2015;35:12917\u201331.","journal-title":"J Neurosci."},{"key":"761_CR44","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/B978-0-12-420118-7.00012-3","volume":"69","author":"BM Kivell","year":"2014","unstructured":"Kivell BM, Ewald AW, Prisinzano TE. Salvinorin A analogs and other \u03ba-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol. 2014;69:481\u2013511.","journal-title":"Adv Pharmacol."},{"key":"761_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00213-010-1825-8","volume":"210","author":"S Wee","year":"2010","unstructured":"Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology. 2010;210:121\u201335.","journal-title":"Psychopharmacology."},{"key":"761_CR46","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1038\/sj.bjp.0704640","volume":"135","author":"JJ Zhou","year":"2002","unstructured":"Zhou JJ, Bian JS, Pei JM, Wu S, Li HY, Wong TM. Role of protein kinase C-epsilon in the development of kappa-opioid receptor tolerance to U50,488H in rat ventricular myocytes. Br J Pharmacol. 2002;135:1675\u201384.","journal-title":"Br J Pharmacol."},{"key":"761_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0092-8674(02)00613-X","volume":"108","author":"L He","year":"2002","unstructured":"He L, Fong J, von Zastrow M, Whistler JL. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell. 2002;108:271\u201382.","journal-title":"Cell."},{"key":"761_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0014-2999(93)90167-G","volume":"243","author":"DP Devine","year":"1993","unstructured":"Devine DP, Leone P, Wise RA. Mesolimbic dopamine neurotransmission is increased by administration of mu-opioid receptor antagonists. Eur J Pharmacol. 1993;243:55\u201364.","journal-title":"Eur J Pharmacol."},{"key":"761_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1124\/jpet.114.216820","volume":"352","author":"KL White","year":"2015","unstructured":"White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK, et al. The G protein-biased \u03ba-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther. 2015;352:98\u2013109.","journal-title":"J Pharmacol Exp Ther."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00761-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00761-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00761-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T08:39:40Z","timestamp":1654072780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00761-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00761-x","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]},"assertion":[{"value":"30 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}